Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study
Source: View publication →
The PARTNER2 study provided definitive clinical evidence that the risk of HIV transmission through condomless anal sex is effectively zero when the HIV-positive partner is maintained on virally suppressive antiretroviral therapy.
Key Findings
Study Design
Study Limitations
Clinical Significance
By demonstrating zero linked transmissions across more than 76,000 condomless anal sex acts, PARTNER2 definitively validated the 'Undetectable = Untransmittable' (U=U) principle for men who have sex with men (MSM). This provides foundational, unassailable evidence for modern HIV public health messaging, helping to dismantle HIV-related stigma, drastically improve the psychological well-being of people living with HIV, incentivize early ART initiation, and scientifically challenge outdated HIV criminalization laws.
Historical Context
Prior to PARTNER2, the landmark HPTN 052 trial and the first phase of the PARTNER study (PARTNER1) established that ART prevents sexual transmission of HIV in heterosexual couples. However, because receptive anal sex carries a significantly higher biological risk of HIV transmission than vaginal sex, rigorous statistical evidence was needed to confirm if viral suppression could completely eliminate transmission risk among MSM. PARTNER2 was specifically designed as an extension study to definitively close this evidence gap, providing the statistical precision necessary to confirm U=U for gay men.
Guided Discussion
High-yield insights from every perspective
What is the biological mechanism by which antiretroviral therapy (ART) prevents sexual transmission of HIV, and what does the concept U=U mean in the context of the PARTNER2 study?
Key Response
ART suppresses viral replication by inhibiting key viral enzymes like reverse transcriptase, integrase, or protease, dropping the viral load in blood and genital secretions to undetectable levels. U=U stands for Undetectable equals Untransmittable, a concept definitively supported by PARTNER2 showing zero linked transmissions when the HIV-positive partner's viral load is under 200 copies per mL.
How should the results of the PARTNER2 study change your clinical counseling for a newly diagnosed HIV-positive MSM patient and their HIV-negative partner regarding condom use, PrEP, and STI prevention?
Key Response
Residents should counsel that while suppressive ART effectively eliminates HIV transmission risk (making PrEP for the negative partner unnecessary if the positive partner is consistently undetectable and they are strictly monogamous), it does not protect against other STIs like syphilis or gonorrhea. Condom use is still recommended depending on the couple's outside sexual networks.
In the PARTNER2 study, 15 HIV-negative partners did acquire HIV, but the transmissions were not phylogenetically linked to their main partner. How does phylogenetic analysis work in this context, and why is it crucial for determining the true efficacy of Treatment as Prevention (TasP)?
Key Response
Phylogenetic analysis sequences viral genes (like pol and env) from both partners to construct an evolutionary tree. If the viral strains do not cluster together, the transmission came from outside the relationship. This is critical in TasP studies because without it, outside acquisitions would falsely lower the perceived efficacy of suppressive ART, masking the true zero-transmission rate from the suppressed partner.
Beyond the biological prevention of transmission, how does integrating the definitive zero-risk findings of PARTNER2 into your clinical practice alter the psychological care and societal stigma management for patients living with HIV?
Key Response
The U=U message fundamentally transforms patient identity, lifting the profound psychological burden of feeling infectious or dangerous to loved ones. Attendings should use this data not just for epidemiological control, but as a therapeutic tool to improve patient mental health, encourage strict ART adherence, and actively combat internalized and external stigma.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The PARTNER2 study reported a transmission rate of 0.00 with a 95 percent confidence interval upper bound of 0.23 per 100 couple-years. From a statistical and epidemiological standpoint, why is it impossible to prove a risk is mathematically zero, and how do we determine if an upper bound is tight enough to inform public health policy?
Key Response
In frequentist statistics, observing zero events yields a point estimate of zero, but the upper bound of the CI depends heavily on the person-years of follow-up. Proving absolute zero is impossible. The upper bound of 0.23 means the true risk could theoretically be up to 1 in roughly 435 years of condomless sex, demonstrating the necessity of massively powered, multi-year observational cohorts to narrow the CI to a level deemed practically zero by public health experts.
As a peer reviewer assessing the PARTNER2 manuscript, what are the primary methodological threats to validity regarding self-reported sexual behavior and viral load monitoring intervals, and how did the authors attempt to mitigate them?
Key Response
A rigorous reviewer would flag recall bias in self-reported condomless anal sex acts and the risk of unmeasured viral load blips between testing intervals. The authors mitigated this through prospective questionnaire designs and frequent viral load testing (censoring data where gaps between tests were too large), though transient viremia remains a theoretical but practically insignificant unmeasured confounder.
Based on the PARTNER2 results, how should WHO and CDC guidelines regarding HIV Treatment as Prevention (TasP) and PrEP indications for serodiscordant MSM couples be updated, and what Level of Evidence does this study provide?
Key Response
PARTNER2 provides strong prospective cohort evidence that acts as Level I for TasP, given the ethical impossibility of an RCT for this question. Current CDC and WHO guidelines now explicitly endorse U=U. Guidelines should clearly state that PrEP is not indicated for the negative partner in a monogamous relationship if the positive partner has documented, sustained viral suppression for at least 6 months, thereby shifting public health resources to individuals at actual risk.
Clinical Landscape
Noteworthy Related Trials
HPTN 052 Trial
Tested
Early initiation of ART
Population
HIV-serodiscordant predominantly heterosexual couples
Comparator
Delayed ART initiation
Endpoint
Linked HIV transmission
PARTNER 1 Study
Tested
Suppressive ART
Population
HIV-serodiscordant heterosexual and MSM couples
Comparator
None (Observational cohort)
Endpoint
Phylogenetically linked HIV transmission
Opposites Attract Study
Tested
Suppressive ART
Population
HIV-serodiscordant male homosexual couples
Comparator
None (Observational cohort)
Endpoint
Phylogenetically linked HIV infections
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis